In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ossianix Inc.

http://www.ossianix.com

Latest From Ossianix Inc.

Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons

Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.

Business Strategies Companies

Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis

Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.

Deals Business Strategies

Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix

Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.

Deals Metabolic Disorders

Start-Up Execs On The Move, March 2012

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register